Idexx Laboratories Stock Today
| IDXX Stock | USD 422.13 0.02 0% |
PerformanceWeak
| Odds Of DistressLow
|
IDEXX Laboratories is trading at 422.13 as of the 20th of March 2025; that is 0.0047 percent decrease since the beginning of the trading day. The stock's open price was 422.15. IDEXX Laboratories has less than a 9 % chance of experiencing financial distress in the next few years but had a somewhat weak performance during the last 90 days. Note, on February 13, 2024, Senator Tommy Tuberville of US Senate acquired under $15k worth of IDEXX Laboratories's common stock.
Business Domain Health Care Equipment & Services | IPO Date 21st of June 1991 | Category Healthcare | Classification Health Care |
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine. The company has 81.33 M outstanding shares of which 2.11 M shares are currently shorted by private and institutional investors with about 3.55 trading days to cover. More on IDEXX Laboratories
Moving against IDEXX Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
IDEXX Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Jonathan Mazelsky | ||||
| Thematic Idea | Healthcare (View all Themes) | ||||
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, Healthcare, Health Care, Health Care Equipment & Supplies, Diagnostics & Research, Healthcare (View all Sectors) | ||||
| Excise Tax Activities | Animal Testing | ||||
| Average Analyst Recommendation | |||||
Debt LevelsIDEXX Laboratories can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand IDEXX Laboratories' financial leverage. It provides some insight into what part of IDEXX Laboratories' total assets is financed by creditors.
| |||||
IDEXX Laboratories (IDXX) is traded on NASDAQ Exchange in USA. It is located in One IDEXX Drive, Westbrook, ME, United States, 04092 and employs 11,000 people. IDEXX Laboratories is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 34.33 B. IDEXX Laboratories conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 81.33 M outstanding shares of which 2.11 M shares are currently shorted by private and institutional investors with about 3.55 trading days to cover.
IDEXX Laboratories currently holds about 114.36 M in cash with 929 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.37.
Check IDEXX Laboratories Probability Of Bankruptcy
Ownership AllocationIDEXX Laboratories has a total of 81.33 Million outstanding shares. The majority of IDEXX Laboratories outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in IDEXX Laboratories to benefit from reduced commissions. Thereupon, third-party entities are subject to a different set of regulations than regular investors in IDEXX Laboratories. Please pay attention to any change in the institutional holdings of IDEXX Laboratories as this could imply that something significant has changed or is about to change at the company. On February 13, 2024, Senator Tommy Tuberville of US Senate acquired under $15k worth of IDEXX Laboratories's common stock.
Check IDEXX Ownership Details
IDEXX Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Norges Bank | 2024-12-31 | 997.1 K | |
| Northern Trust Corp | 2024-12-31 | 912.9 K | |
| Franklin Resources Inc | 2024-12-31 | 867.1 K | |
| Fundsmith Investment Services Ltd. | 2024-12-31 | 865 K | |
| American Century Companies Inc | 2024-12-31 | 809.8 K | |
| Ubs Asset Mgmt Americas Inc | 2024-12-31 | 785.9 K | |
| Amundi | 2024-12-31 | 758.7 K | |
| Principal Financial Group Inc | 2024-12-31 | 711.2 K | |
| Capital Research Global Investors | 2024-12-31 | 616 K | |
| Vanguard Group Inc | 2024-12-31 | 9.7 M | |
| Blackrock Inc | 2024-12-31 | 8.5 M |
IDEXX Laboratories Historical Income Statement
IDEXX Stock Against Markets
IDEXX Laboratories Corporate Management
| Jeffrey Carr | GM VP | Profile | |
| Sharon JD | General VP | Profile | |
| Nimrata PE | Executive Commercial | Profile | |
| Julie Godon | Senior Officer | Profile | |
| Emilia Bostater | Officer Architecture | Profile |
Additional Tools for IDEXX Stock Analysis
When running IDEXX Laboratories' price analysis, check to measure IDEXX Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IDEXX Laboratories is operating at the current time. Most of IDEXX Laboratories' value examination focuses on studying past and present price action to predict the probability of IDEXX Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IDEXX Laboratories' price. Additionally, you may evaluate how the addition of IDEXX Laboratories to your portfolios can decrease your overall portfolio volatility.